Larsen M L
Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health Sciences University, Portland, Oregon, USA.
Curr Opin Lipidol. 1994 Feb;5(1):42-7. doi: 10.1097/00041433-199402000-00008.
The recently revised guidelines for cholesterol management in Europe and the USA have focused attention on triglycerides and HDL cholesterol as risk factors for coronary heart disease. In the present review, I shall discuss therapeutic considerations in the treatment of patients with hypertriglyceridemia or low HDL cholesterol in the context of these new recommendations. I shall also consider recent studies in which the effect of triglyceride-lowering drugs on the concentrations and metabolism of lipoproteins in patients with dyslipidemia are evaluated.
欧洲和美国最近修订的胆固醇管理指南已将注意力集中在甘油三酯和高密度脂蛋白胆固醇作为冠心病的危险因素上。在本综述中,我将在这些新建议的背景下讨论高甘油三酯血症或低高密度脂蛋白胆固醇患者治疗中的治疗考虑因素。我还将考虑最近的研究,其中评估了降甘油三酯药物对血脂异常患者脂蛋白浓度和代谢的影响。